Home » About the AACR » Newsroom »
SAN ANTONIO – Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had...
Mutations were detected via circulating tumor DNA before disease progression in patients treated with an aromatase inhibitor/palbociclib for hormone...
Concurrent treatment with PI3K pathway inhibitors may benefit at-risk patients SAN ANTONIO – Uterine cancers that developed in patients...
Tumor biology, not race, was a more significant factor in predicting response to clinical trial treatment SAN ANTONIO – Analysis...
SAN ANTONIO – Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was...
Elacestrant is the first oral selective estrogen receptor degrader to show clinical benefit over standard of care in a...
Imaging mass cytometry was feasible in a large clinical trial of atezolizumab in combination with chemotherapy SAN ANTONIO –...
The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) was highly predictive of the benefits of targeted therapies...
Next-generation sequencing for minimal residual disease was highly sensitive and more accurate than flow cytometry and monitoring of B-cell...
PHILADELPHIA – Today, the American Association for Cancer Research (AACR) and Pelotonia announced the establishment of a new grants...